Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT07529782
What this trial is testing

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma and Other Plasma Cell Neoplasms
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 15
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07614360
What this trial is testing

Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 150
Post-approval studies (Phase 4)Study completedNCT03768960
What this trial is testing

DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

Who this might be right for
Multiple Myeloma
Johnson & Johnson Private Limited 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT07150091
What this trial is testing

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 20
Early research (Phase 1)Study completedNCT02616640
What this trial is testing

Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 114
Large-scale testing (Phase 3)Active Not RecruitingNCT05552976
What this trial is testing

Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb 606
Large-scale testing (Phase 3)Study completedNCT00005805
What this trial is testing

St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer

Who this might be right for
Chronic Myeloproliferative DisordersFatigueLeukemia+5 more
Memorial Sloan Kettering Cancer Center
Not applicableStudy completedNCT01053494
What this trial is testing

Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Undifferentiated LeukemiaAngioimmunoblastic T-cell Lymphoma+84 more
Wake Forest University Health Sciences 80
Early research (Phase 1)Looking for participantsNCT04162353
What this trial is testing

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Who this might be right for
Multiple Myeloma in RelapseRefractory Multiple MyelomaPlasmacytoid; Lymphoma
iCell Gene Therapeutics 12
Testing effectiveness (Phase 2)Looking for participantsNCT06421675
What this trial is testing

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple Myeloma
Ontario Clinical Oncology Group (OCOG) 40
Testing effectiveness (Phase 2)Ended earlyNCT03256045
What this trial is testing

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
University of Washington 9
Early research (Phase 1)Study completedNCT00003395
What this trial is testing

Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT07382739
What this trial is testing

Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

Who this might be right for
Phase 2Radiotherapy-Induced Immune PrimingElranatamab+4 more
M.D. Anderson Cancer Center 34
Testing effectiveness (Phase 2)Study completedNCT04445701
What this trial is testing

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Arch Oncology 10
Early research (Phase 1)Study completedNCT04045795
What this trial is testing

Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Sanofi 56
Testing effectiveness (Phase 2)Study completedNCT02176213
What this trial is testing

Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Ajai Chari 35
Large-scale testing (Phase 3)WithdrawnNCT06232707
What this trial is testing

Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Celgene
Early research (Phase 1)Study completedNCT02189343
What this trial is testing

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 16
Testing effectiveness (Phase 2)Study completedNCT00049504
What this trial is testing

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+94 more
Fred Hutchinson Cancer Center 53
Very early researchUnknownNCT04236011
What this trial is testing

BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 15
Next Page